T cells that recognize particular self Ags are thought to be important in t
he pathogenesis of autoimmune diseases. In multiple sclerosis, susceptibili
ty is associated with HLA-DR2, which can present myelin-derived peptides to
CD4(+) T cells. To generate molecules that target such T cells based on th
e specificity of their TCR, we expressed a soluble dimeric DR2-IgG fusion p
rotein with a bound peptide from myelin basic protein (MBP). Soluble, dimer
ic DR2/MBP peptide complexes activated MBP-specific T cells in the absence
of signals from costimulatory or adhesion molecules. This initial signaling
through the TCR rendered the T cells unresponsive (anergic) to subsequent
activation by peptide-pulsed APCs. Fluorescent labeling demonstrated that a
nergic T cells were initially viable, but became susceptible to late apopto
sis due to insufficient production of cytokines. Dimerization of the TCR wi
th bivalent MHC class II/peptide complexes therefore allows the induction o
f anergy inhuman CD4(+) T cells with a defined MHC/peptide specificity.